Design, Synthesis, Biological Evaluation, and Computational Studies of Pyrazine‐1,3,4‐Oxadiazole Analogs as Potential Antitubercular Agents
Chemistry & Biodiversity · 13.06.2025
DOI: 10.1002/cbdv.202500777 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, online erschienen am 13.06.2025. Verfasst von Asha Ganesh Suryawanshi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Shri. D. D. Vispute College of Pharmacy and Research Centre, New Panvel East, Navi Mumbai, Maharashtra, India. Hauptthemen laut MEDLINE: Antitubercular Agents, Oxadiazoles, Mycobacterium tuberculosis, Drug Design. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 57 Literaturangaben.
Abstract (Originalsprache)
Tuberculosis (TB) remains a major global health threat, with Mycobacterium tuberculosis (Mtb) causing high morbidity and mortality. The rise of multidrug‐resistant TB (MDR‐TB) and extensively drug‐resistant TB (XDR‐TB) necessitates novel therapeutics with improved efficacy and safety. Among heterocyclic frameworks, pyrazine and oxadiazole derivatives have shown promising antimycobacterial activity. Pyrazinamide is a key pyrazine‐based drug, whereas 1,3,4‐oxadiazoles exhibit strong enzyme inhibition. In this study, a series of pyrazine‐1,3,4‐oxadiazole derivatives were synthesized and characterized using infrared (IR), mass spectrometry, nuclear magnetic resonance (NMR), and elemental analysis. Their antitubercular activity was evaluated against the Mtb H 37 Rv strain using the microplate alamar blue assay (MABA). The compounds exhibited minimum inhibitory concentration (MIC) values ranging from 3.13 to 12.5 µg/mL (9.39–55.75 µM). Notably, compounds 2e , 2f , and 2n exhibited the highest potency, attributed to halogen substitutions that enhanced lipophilicity and target interactions. Molecular docking studies reinforced these results, with compound 2f demonstrating a strong binding affinity (−9.0 kcal/mol) for the DprE1 enzyme, surpassing standard anti‐TB drugs, isoniazid (−5.3 kcal/mol) and rifampicin (−7.9 kcal/mol). In addition, molecular dynamics (MD) simulation results revealed that compound 2f exhibits superior structural stability, compactness, and consistent binding interactions with DprE1. These findings highlight the potential of pyrazine‐oxadiazole hybrids as promising scaffolds for developing novel antitubercular agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Shri. D. D. Vispute College of Pharmacy and Research Centre, New Panvel East, Navi Mumbai, Maharashtra, India.
- Department of Pharmaceutical Chemistry, Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat, India.
- Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.
ORCID-Profile: Uma Dhiraj Kabra
Zitieren
APA
Suryawanshi, A. G., Pathak, C., Khona, P., Jain, A., & Kabra, U. D. (2025). Design, Synthesis, Biological Evaluation, and Computational Studies of Pyrazine‐1,3,4‐Oxadiazole Analogs as Potential Antitubercular Agents. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202500777
Vancouver
Suryawanshi AG, Pathak C, Khona P, Jain A, Kabra UD. Design, Synthesis, Biological Evaluation, and Computational Studies of Pyrazine‐1,3,4‐Oxadiazole Analogs as Potential Antitubercular Agents. Chemistry & Biodiversity. 2025. doi:10.1002/cbdv.202500777
BibTeX
@article{Suryawanshi2025,
author = {Suryawanshi, Asha Ganesh and Pathak, Chandni and Khona, Pratik and Jain, Ashish and Kabra, Uma Dhiraj},
title = {Design, Synthesis, Biological Evaluation, and Computational Studies of Pyrazine‐1,3,4‐Oxadiazole Analogs as Potential Antitubercular Agents},
journal = {Chemistry & Biodiversity},
year = {2025},
doi = {10.1002/cbdv.202500777}
}
EUVIMED